How Common Is It
Enjoy a limited-time welcome discount on your first visit
The group at risk of endometrial hyperplasia are those women using a GLP-1 and also using TD oestrogen (which will be unaffected by the GLP-1 agonist) and an oral progestogen, as the absorption of the progestogen may be reduced while the oestrogen stays the same, leaving the woman with an unbalanced regime and an insufficient amount of progestogen to protect her endometrium from the oestrogen
The full itemized breakdown is published on the HealthiCare website - not buried in an FAQ or hidden behind an intake form
Since the latter are thought to exert their glucose-lowering activity by preventing the degradation and inactivation (with regard to insulinotropic effects) of endogenously released intact, biologically active GLP-1 [9], their pharmacological action should critically depend on availability of the major substrate, GLP-1
The program includes your GLP-1 vial, syringes/needles, office visit follow-ups, and any communication made via phone/text with our medical staff
